中文名稱  心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 

英文名稱  Anti-Ryanodine Receptor

別    名 Arrhythmogenic right ventricular dysplasia 2; ARVC 2; ARVC2; ARVD 2; ARVD2; Brain ryanodine receptor calcium release channel; Brain type ryanodine receptor; Cardiac muscle ryanodine receptor; Cardiac muscle ryanodine receptor calcium release channel; Cardiac muscle type ryanodine receptor; CCO; Central core disease of muscle; HBRR; hRYR 2; hRYR2; MHS; MHS1; Ryanodine receptor 1 (skeletal); Ryanodine receptor 1; Ryanodine receptor 2 (cardiac); Ryanodine receptor 2; Ryanodine receptor 3; Ryanodine receptor type1; RYDR; RYR 1; RYR 2; RYR 3; RYR; RYR1; RYR2; RYR3; Sarcoplasmic reticulum calcium release channel; Skeletal muscle calcium release channel; Skeletal muscle ryanodine receptor; Skeletal muscle type ryanodine receptor; SKRR; Type 1 like ryanodine receptor; VTSIP.

產(chǎn)品屬性：

心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Rabbit

產(chǎn)品類型   一抗  

研究領(lǐng)域     心 通道蛋白 細胞膜受體

蛋白分子量  predicted molecular weight: 566kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human Ryanodine Receptor

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 產(chǎn)品應(yīng)用   ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 The Ryanodine Receptor (RyR) is the channel responsible for calcium release from muscle cell Sarcoplasmic Reticulum (SR) and also plays a role in calcium regulation in non-muscle cells. The RyR exists as a homotetramer and is predicted to have a short cytoplasmic C-terminus and 4-10 transmembrane domains. The remainder of the protein, termed the "foot" region, is located in the cytoplasm between the transverse tubule and the SR. Mammalian RyR isoforms are the product of three different genes: RyR-1 is expressed predominantly in skeletal muscle and areas of the brain; RyR-2 is expressed predominantly in heart muscle but also found in the stomach, endothelial cells and diffuse areas of the brain; and RyR-3 is found in smooth muscle and the brain (striatum, thalamus and hippocampus). In non-mammalian vertebrates, the RyR isoforms are termed alpha, beta and cardiac which correlate loosely to the mammalian RyR-1, RyR-3 and RyR-2 isoforms respectively.

Function : Calcium channel that mediates the release of Ca(2+) fromthe sarcoplasmic reticulum into the cytoplasm and thereby plays akey role in triggering muscle contraction following depolarizationof T-tubules. Repeated very high-level exercise increases the openprobability of the channel and leads to Ca(2+) leaking into thecytoplasm. Can also mediate the release of Ca(2+) fromintracellular stores in neurons, and may thereby promote prolongedCa(2+) signaling in the brain. Required for normal embryonicdevelopment of muscle fibers and skeletal muscle. Required fornormal heart morphogenesis, skin development and ossificationduring embryogenesis (By similarity).

Subunit : Homotetramer. Can also form heterotetramers with RYR2.Interacts with CALM; CALM with bound calcium inhibits the RYR1channel activity. Interacts with S100A1. Interacts with FKBP1A;this stabilizes the closed conformation of the channel. Interactswith CACNA1S; interaction with CACNA1S is important for activationof the RYR1 channel. Interacts with CACNB1. Interacts with TRDN andASPH; these interactions stimulate RYR1 channel activity (Bysimilarity). Identified in a complex composed of RYR1, PDE4D, PKA,FKBP1A and protein phosphatase 1 (PP1). Repeated very high-levelexercise decreases interaction with PDE4D and protein phosphatase 1(PP1).

Subcellular Location : Sarcoplasmic reticulum membrane; Multi-pass membrane protein (Probable). Membrane; Multi-pass membrane protein. Microsome membrane; Multi-pass membrane protein.

Tissue Specificity : Brain, skeletal muscle, placenta and possibly liver and kidney. In brain, highest levels are found in the cerebellum, hippocampus, caudate nucleus and amygdala, with lower levels in the corpus callosum, substantia nigra and thalamus.

Post-translational modifications : Channel activity is modulated by phosphorylation.Phosphorylation at Ser-2843 may increase channel activity. Repeatedvery high-level exercise increases phosphorylation at Ser-2843.[PTM] Activated by reversible S-nitrosylation. Repeated veryhigh-level exercise increases S-nitrosylation.

DISEASE : Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomaldominant pharmacogenetic disorder of skeletal muscle and is one ofthe main causes of death due to anesthesia. In susceptible people,an MH episode can be triggered by all commonly used inhalationalanesthetics such as halothane and by depolarizing muscle relaxantssuch as succinylcholine. The clinical features of the myopathy arehyperthermia, accelerated muscle metabolism, contractures,metabolic acidosis, tachycardia and death, if not treated with thepostsynaptic muscle relaxant, dantrolene. Susceptibility to MH canbe determined with the 'in vitro' contracture test (IVCT):observing the magnitude of contractures induced in strips of muscletissue by caffeine alone and halothane alone. Patients with normalresponse are MH normal (MHN), those with abnormal response tocaffeine alone or halothane alone are MH equivocal (MHE(C) andMHE(H) respectively). Note=The disease is caused by mutationsaffecting the gene represented in this entry.

Central core disease of muscle (CCD) [MIM:117000]:Autosomal dominant congenital myopathy, but a severe autosomalrecessive form also exists. Both clinical and histologicalvariability is observed. Affected individuals typically displayhypotonia and proximal muscle weakness in infancy, leading to thedelay of motor milestones. The clinical course of the disorder isusually slow or nonprogressive in adulthood, and the severity ofthe symptoms may vary from normal to significant muscle weakness.Microscopic examination of CCD-affected skeletal muscle reveals apredominance of type I fibers containing amorphous-looking areas(cores) that do not stain with oxidative and phosphorylasehistochemical techniques. Note=The disease is caused by mutationsaffecting the gene represented in this entry.

Multiminicore disease with external ophthalmoplegia(MMDO) [MIM:255320]: Clinically heterogeneous neuromusculardisorder. General features include neonatal hypotonia, delayedmotor development, and generalized muscle weakness and amyotrophy,which may progress slowly or remain stable. Muscle biopsy showsmultiple, poorly circumscribed, short areas of sarcomeredisorganization and mitochondria depletion (areas termed minicores)in most muscle fibers. Typically, no dystrophic signs, such asmuscle fiber necrosis or regeneration or significant endomysialfibrosis, are present in multiminicore disease. Note=The disease iscaused by mutations affecting the gene represented in this entry.

Congenital myopathy with fiber-type disproportion (CFTD)[MIM:255310]: Genetically heterogeneous disorder in which there isrelative hypotrophy of type 1 muscle fibers compared to type 2fibers on skeletal muscle biopsy. However, these findings are notspecific and can be found in many different myopathic andneuropathic conditions. Note=The disease is caused by mutationsaffecting the gene represented in this entry.

Note=Defects in RYR1 may be a cause of Samaritanmyopathy, a congenital myopathy with benign course. Patientsdisplay severe hypotonia and respiratory distress at birth. Unlikeother congenital myopathies, the health status constantly improvesand patients are minimally affected at adulthood.

Similarity : Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR3 subfamily.

Contains 3 B30.2/SPRY domains.

Contains 5 MIR domains.

Database links : UniProtKB/Swiss-Prot: P21817.3

Defects in the RYR2 gene are the cause of several heart diseases: 1) familial arrhythmogenic right ventricular dysplasia 2 (ARVD2), also known as arrhythmogenic right ventricular cardiomyopathy 2 (ARVC2), 2) an autosomal dominant form of stress-induced polymorphic ventricular tachycardia (VTSIP), also known as catecholaminergic polymorphic ventricular tachycardia (CPVT) and 3) familial polymorphic ventricular tachycardia (FPVT). Ryanodine Receptor 2 contains several phosphorylatable sites. Specifically, Ser-2030 and Ser-2809 (or at Ser-2808 depending on the species) can be phosphoryated by protein kinase A (PKA) and Ser-2815 (or at Ser-2814 depending on the species) can be phosphorylated by CaMKII (Ca2+/calmodulin-dependent protein kinase II).

實驗流程：

全、新、優(yōu)、品、好四大特點：

心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

技術(shù)外包服務(wù):

★心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構(gòu)建、細胞RNAi技術(shù)等等。

正在熱銷的相關(guān)產(chǎn)品：

LRP/MVP (Lung resistance related protein) 肺耐藥相關(guān)蛋白(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-CR1/CD35 Ⅰ型補體受體抗體(C3b/C4b受體抗體)Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh PABP 多聚腺苷酸結(jié)合蛋白抗體 規(guī)格 0.1ml

STK4 Kit Human 人 STK4 / MST1 ELISA配對抗體 ELISA

TUBA4A 英文名稱： 微管蛋白4α抗體 0.1ml

CD73 英文名稱： CD73抗體 0.2ml

Anti-CR1/CD35 Ⅰ型補體受體抗體(C3b/C4b受體抗體)Multi-class antibodies規(guī)格： 0.2ml

Anti-Regucalcin/SMP30/Rgn/FITC 熒光素標(biāo)記衰老標(biāo)記蛋白30抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Bursin 囊素三肽/三肽囊素/雞法氏囊三肽Multi-class antibodies規(guī)格： 100mg

抗蚯蚓纖溶酶抗體/抗蚓激酶抗體 Anti-Lumbrokinase 0.1ml

Selenium Binding Protein 1 英文名稱： 硒結(jié)合蛋白1抗體 0.2ml

FOXB1 + FOXB2 英文名稱： 叉頭蛋白B1+B2抗體 0.2ml

Rhesus antibody Rh Phospho-PKC gamma (Thr514) 磷酸化蛋白激酶C亞型G抗體 規(guī)格 0.1ml

Bursin 囊素三肽/三肽囊素/雞法氏囊三肽Multi-class antibodies規(guī)格： 100mg

IL-11 小鼠白介素-11Multi-class antibodies規(guī)格： 48T

Anti-ERK2/MAPK1 原活化蛋白激酶1抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh MT-ND1 NADH復(fù)合體1抗體 規(guī)格 0.2ml

F X III (Human coagulation factor X III ) ELISA Kit 人凝血因子ⅩⅢ 96T

Striatin 3 英文名稱： 細胞周期蛋白SG2N抗體 0.2ml

connexin 30 英文名稱： 間隙連接蛋白30抗體 0.1ml

Anti-ERK2/MAPK1 原活化蛋白激酶1抗體Multi-class antibodies規(guī)格： 0.1ml

布氏瓊脂250g用于彎曲桿菌的抗生素敏感性試驗和純化培養(yǎng)。

ISP培養(yǎng)基 250g 用于鏈霉菌的培養(yǎng)

李氏菌增菌肉湯(LB1,LB2)基礎(chǔ) Listeria Enrichment Broth Base 250 添加奈啶酮酸，黃素，即為LB1，LB2，用于李氏菌二步增菌(GB標(biāo)準(zhǔn))

卵黃氯瓊脂培養(yǎng)基250g/瓶用于金黃色葡萄球菌選擇性分離，每65ml培養(yǎng)基中添加2支20804incubationmedia卵黃氯瓊脂培養(yǎng)基250g/瓶用于金黃色葡萄球菌選擇性分離，每65ml培養(yǎng)基中添加2支20804

MUG快速鑒定大腸試劑 5ml*10支/盒 用于快速鑒定大腸桿菌

水稻水培養(yǎng)液250g用于水稻的水培養(yǎng)液

金黃色葡萄球菌顯色培養(yǎng)基 用于金黃色葡萄球菌的鑒定和計數(shù) 1000ml incubation media 金黃色葡萄球菌顯色培養(yǎng)基 用于金黃色葡萄球菌的鑒定和計數(shù) 1000ml

寬鱗大孔菌 啤酒 (下層酵母)。 支/瓶

MUG

1%Tween80-CornAgarMedium

心肌蘭尼堿受體抗體（腦肌蘭尼堿受體）品牌 氧氣指示劑  規(guī)格：  10片/包  用途：  一片/次，可重復(fù)

3.5L厭氧產(chǎn)氣劑  規(guī)格：  10袋/包  用途：  嚴(yán)格厭氧菌培養(yǎng)：每袋用于3.5L厭氧體積。

2.5LCO2產(chǎn)氣劑  規(guī)格：  10袋/包  用途：  嗜二氧化碳菌培養(yǎng)：每袋用于2.5L厭氧體積。

2.5L微需氧產(chǎn)氣劑  規(guī)格：  10袋/包  用途：  微需氧菌培養(yǎng)：每袋用于2.5L厭氧體積。